Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

TOKYO, Sep 12, 2022 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today results from a post hoc analysis of three randomized, pivotal, Phase 3 studies (EMBRACE trial/Study 305, Study 301 and Study304) evaluating the efficacy of eribulin mesylate (marketed as HALAVEN) versus other chemotherapies (Treatment of Physician's...

Decoupling viewed as risky bet for US

A customer shops at a supermarket in Millbrae, California, the United States, Aug 10, 2022. (PHOTO / XINHUA) Economic wager driven by anti-China policies leaves no winners, experts say The US government's policies toward China are putting the country on the wrong track, according to China watchers who stress that...